Stockscreener 앱 받기
1.90
2.56%
-0.05
시간 외 거래:
1.92
0.02
+1.05%
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
Gain Therapeutics to Present at the 38th Annual ROTH Conference - The Manila Times
Gain Therapeutics, Inc. CEO Gene Mack to Speak at 38th Annual ROTH Conference - Quiver Quantitative
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday - MarketBeat
Gain Therapeutics reports biomarker data from Parkinson’s trial By Investing.com - Investing.com South Africa
Gain announces presentations on Phase 1b clinical study of GT-02287 - TipRanks
Gain Therapeutics, Inc. (GANX): Emerging Biomarker Data Strengthens Parkinson’s Drug Pipeline - parameter.io
Gain Therapeutics Presents Positive Phase 1b Results for GT-02287 in Parkinson’s Disease and Advances New GCase Modulators for Clinical Development 123 - Minichart
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data - TipRanks
Gain Presents Phase 1b GT-02287 Data Showing biomarker changes, MDS-UPDRS stability; GT-04686 ready for IND - TradingView
Gain Therapeutics (NASDAQ: GANX) unveils new Parkinson’s trial and biomarker data - Stock Titan
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 - Bitget
Gain Therapeutics reports biomarker data from Parkinson’s trial - Investing.com
Parkinson’s trial drug sees symptoms hold steady over 5 months - Stock Titan
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can Gain Therapeutics Inc stock double in the next yearWeekly Investment Summary & Expert Curated Trade Ideas - baoquankhu1.vn
Aug Drivers: Whats the beta of Gain Therapeutics Inc stock2026 Weekly Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7%What's Next? - MarketBeat
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next? - Defense World
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD) - The Globe and Mail
Gain Therapeutics (GANX) upgraded to buy: Here's why - MSN
Is Gain Therapeutics Inc vulnerable to short sellersWeekly Profit Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update - Bitget
Market Recap: Is Gain Therapeutics Inc part of any major indexWeekly Gains Report & Risk Managed Investment Signals - baoquankhu1.vn
GANX Technical Analysis & ETF Price Forecast - Intellectia AI
What makes Gain Therapeutics Inc. stock attractive to growth fundsCEO Change & Expert Curated Trade Ideas - Naître et grandir
Pharma News: Can Gain Therapeutics Inc continue delivering strong returnsMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Bearish Setup: What is Gain Therapeutics Incs 5 year growth outlookTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
GANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Voyager Therapeutics Inc. stock gain from lower inflationTrade Analysis Report & Daily Oversold Stock Bounce Ideas - mfd.ru
Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
GANX PE Ratio & Valuation, Is GANX Overvalued - Intellectia AI
Intellia Therapeutics Opens with 6.49% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Gain Therapeutics to Present Key Clinical Program Updates at Oppenheimer Conference - AD HOC NEWS
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - 富途牛牛
What’s the beta of Gain Therapeutics Inc. stock2025 Short Interest & Detailed Earnings Play Alerts - mfd.ru
What’s the analyst consensus on Gain Therapeutics Inc.Weekly Trade Review & Risk Controlled Swing Alerts - mfd.ru
Can Gain Therapeutics Inc. stock double in the next yearBreakout Watch & Weekly High Return Forecasts - mfd.ru
Aug Summary: Is Gain Therapeutics Inc stock a falling knife or bargain buyJuly 2025 Technicals & Growth-Oriented Investment Plans - baoquankhu1.vn
What dividend safety score for Gain Therapeutics Inc. stockWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
Market Fear: Is Gain Therapeutics Inc a strong candidate for buy and holdAnalyst Upgrade & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January - MarketBeat
Published on: 2026-02-16 00:03:51 - mfd.ru
Is Gain Therapeutics Inc. benefiting from innovation trendsJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - mfd.ru
Will Edgewise Therapeutics Inc. stock gain from government policies2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Insider Trends: Whats the beta of Themes Etf Trust Leverage Shares 2x Long Panw Daily Etf stockPortfolio Gains Report & Safe Entry Trade Signal Reports - baoquankhu1.vn
Aug Wrap: Whats the analyst consensus on Gain Therapeutics IncJobs Report & Risk Managed Investment Signals - baoquankhu1.vn
Will Entrada Therapeutics Inc. stock gain from lower inflationJuly 2025 Patterns & Long-Term Capital Growth Ideas - mfd.ru
GANX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is Gain Therapeutics Inc. vulnerable to short sellersTrade Risk Summary & Real-Time Market Trend Scan - mfd.ru
Can Gain Therapeutics Inc. continue delivering strong returnsJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - mfd.ru
Is Gain Therapeutics Inc. forming bullish engulfing patternsProfit Target & Low Risk High Reward Trade Ideas - mfd.ru
Critical Contrast: Gain Therapeutics (NASDAQ:GANX) and Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Treasury Yields: What hedge funds are buying Gain Therapeutics IncMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):